NAMS Insider Trading

NewAmsterdam Pharma Company N.V. (NAMS) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $2.36B, listed on NASDAQ, employing roughly 100 people, carrying a beta of 0.10 to the broader market. NewAmsterdam Pharma Company N. Led by Michael Harvey Davidson Facp., public since 2021-02-09.

In the last 12 months, NewAmsterdam Pharma Company N.V. insiders made 1 buy transaction and 43 sale transactions.

DateNameTypeSharesPriceValue
Oct 2, 2026Kastelein Johannes Jacob PieterM-Exempt50,246$0.00$0
Oct 2, 2026Kastelein Johannes Jacob PieterM-Exempt50,246$0.00$0
Oct 2, 2026Kastelein Johannes Jacob PieterS-Sale50,246$25.03$1.3M
Sep 15, 2026Davidson Michael H.P-Purchase10,000$22.65$226.5K
Sep 9, 2026Smither John WS-Sale1,600$25.32$40.5K
Sep 3, 2026Gunning Robert WilliamA-Award14,000$24.92$348.9K
Sep 3, 2026Gunning Robert WilliamA-Award3,200$0.00$0
Aug 25, 2026Kastelein Johannes Jacob PieterM-Exempt125,000$0.00$0
Aug 25, 2026Kastelein Johannes Jacob PieterM-Exempt125,000$0.00$0
Aug 25, 2026Kastelein Johannes Jacob PieterS-Sale125,000$26.91$3.4M

NAMS Insider Activity by Quarter

Reported Form 4 and Form 5 lines under NAMS's own SEC company ID, by transaction date, back to Q4 2024. Purchases and sales are code P / S (open market or private) in the company's shares; other lines are purchases and sales of other securities (options, warrants, preferred), awards, exercises, tax withholding, gifts and other acquisitions and dispositions. Later filings and amendments can change the current quarter. Earlier quarters are not shown: the filings read reach back to Jan 2, 2024, and a quarter counts only when every filing for it was read.

QuarterPurchasesBoughtSalesSoldOther Lines
Q4 2026 (so far)0N/A0N/A0
Q3 20261$226.5K6$7.8M10
Q2 20260N/A3$3.5M8
Q1 20260N/A31$46.7M (30 of 31 priced)48
Q4 20250N/A3$5.2M8
Q3 20253$58.4K10$9.1M8
Q2 20253$236.8K5$5.3M19
Q1 20252$109.7K17$13.1M (15 of 17 priced)65
Q4 20240N/A26$30.7M2

NAMS Institutional Ownership (13F)

As of Jun 30, 2026 (Q2 2026), 195 institutions reported holding 121,990,598 NAMS shares, valued at $4.13B as reported, 102.6% of its market cap (market cap of Jun 26, 2026). That is +24 institutions from the quarter before. Among managers whose reports for both quarters are comparable, 44 opened a position, 19 closed one, 71 added and 50 trimmed.

Top Holders, Q2 2026

ManagerSharesValueChange
Frazier Life Sciences Management, L.P.18,088,902$613.0M+1,145,128
Capital World Investors12,230,557$414.5M+1,121,523
FMR LLC10,339,663$350.4M+1,573,852
RA CAPITAL MANAGEMENT, L.P.9,550,191$323.7MUnchanged
FCPM III SERVICES B.V.8,490,353$287.7M-708,547
DEERFIELD MANAGEMENT COMPANY, L.P.4,264,789$144.5MUnchanged
VIKING GLOBAL INVESTORS LP4,203,567$142.5MUnchanged
Bain Capital Life Sciences Investors, LLC3,806,566$129.0M-3,500,000
MAVERICK CAPITAL LTD3,267,802$110.7M+1,081,400
Duquesne Family Office LLC3,070,146$104.0MUnchanged

By Quarter

QuarterInstitutionsSharesValue
Q2 2026195121,990,598$4.13B
Q1 2026171123,832,049$3.97B
Q4 2025187119,353,693$4.19B
Q3 2025137121,886,713$3.46B
Q2 2025130116,386,650$2.11B
Q1 2025126111,177,846$2.28B
Q4 202413098,611,632$2.53B
Q3 202410077,112,707$1.28B
Q2 20249072,295,212$1.39B

From the SEC's Form 13F data sets: investment managers with $100 million or more in Section 13(f) securities report their holdings each quarter, up to 45 days after it ends; a restated filing replaces the original, and values are as the managers reported them (a position whose price runs about 1,000 times below other managers', from a manager whose positions mostly do, is read as reported in thousands of dollars). The same shares can be reported by more than one manager, so totals can count some twice.

ETFs Holding NAMS

FundWeight of NAMSShares (as reported)Value (as reported)Source updated
CGMM Capital Group U.S. Small and Mid Cap ETF0.47%754,905$16.8MOct 8, 2026
DRKY VistaShares Target 15 DRUKMacro Distribution ETF3.03%29,092$643.8KOct 8, 2026
IBBQ Invesco Nasdaq Biotechnology ETF0.18%8,887$196.7KOct 8, 2026
ACSG American Century Small Cap Growth Insights ETF0.24%5,637$124.7KOct 8, 2026

From each fund's latest holdings file on record that shows NAMS's listed security itself. A file counts when its line count is consistent with the fund's reported holdings count (at most twice it plus 10, or at most 1,000 lines for a reported count of exactly 10, which the data source gives many funds as a cap), read with that file or inherited from the fund's last classified file (within 20% of its line count, read within 60 days). Funds whose line for the company could not be confirmed as NAMS's listed security, or that hold it through underlying funds (look-through), are not listed. Only long positions count: a fund is left out when any of its lines for NAMS reports a negative weight, share count or value, or none of them above zero (a short position, or figures that disagree). Shares, value and weight are as reported in each fund's file, dated by the data source's last update of that file (not the date of the positions); the weight is NAMS's share of that fund.

How to Read NAMS Insider Activity

Net insider sentiment skews to the sell side over the trailing twelve months: 43 sales versus 1 buys. Insider sales carry less informational weight than buys because they are often driven by liquidity, tax planning, or pre-scheduled Rule 10b5-1 trading plans rather than negative information. The transaction type alone does not say whether a sale was made on the open market or privately, or under a 10b5-1 plan; the filing's plan checkbox and footnotes do. The transaction table above includes the filer's reporting name, transaction type, share count, per-share price, and total dollar value where computable. For options traders, insider activity is one input to event-driven sizing alongside earnings calendar, analyst-rating cluster moves, and the implied-vol surface. Form 4 filings (the dominant Section 16 reporting form) must be submitted within two business days of the transaction; clusters of buys across multiple insiders within a short window are the strongest informational pattern. SEC EDGAR carries the underlying source filings for verification and additional historical depth.

Learn how insider trading is reported and how to read the data →

Frequently asked NAMS insider trading questions

How active are NAMS insiders right now?
Over the trailing twelve months, NewAmsterdam Pharma Company N.V. (NAMS) insiders made 1 buy transaction and 43 sale transactions. Net insider sentiment over the trailing twelve months tilts to the sell side (43 sales vs 1 buys). The transaction list above shows the most recent filings; each entry includes the insider's name, transaction type, share count, and per-share price.
What counts as an insider transaction?
Section 16 of the Securities Exchange Act requires officers, directors, and 10% beneficial-owner shareholders to disclose changes in their holdings via Form 3 (initial statement), Form 4 (subsequent transactions, filed within two business days), and Form 5 (annual catch-up). Insider transactions cover open-market purchases and sales, exercise of stock options, gifts, and grants. The "transaction type" field on each row distinguishes these subcategories.
Are NAMS insider buys a bullish signal?
Insider purchases (Type P, made on the open market or privately; the code covers both) carry more informational weight than insider sales: an insider must commit personal capital, and the SEC scrutinizes purchases under Rule 10b5-1 for material non-public information. Sales, by contrast, are often driven by liquidity, tax planning, or pre-scheduled 10b5-1 trading plans rather than negative information. Cluster buying (multiple insiders buying within a short window) is a stronger signal than isolated buys.
How do NAMS insider transactions affect options pricing?
Insider transaction data does not directly drive implied volatility, but Form 4 disclosures can move single-name IV if the size or timing is unusual (e.g. a large CEO buy ahead of an earnings window). Options markets price the marginal informational content; routine transactions under pre-scheduled plans are typically ignored. For event-driven options sizing, pair the insider transaction history with the upcoming earnings calendar.